Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications

Table 1

Summary of prevalence of TKR molecular alterations, divided by the main lung cancer histologies, and examples of TKIs available for every alteration.

Alteration	NSCLC		SCLC	TKI available
	ADC	SCC
EGFR mutation	10–15% [33]	5% [34]	<5% [35]	Erlotinib, Afatinib, Gefitinib, AZD9291, rociletinib
EGFR vIII mutation	Very rare [36, 37]	—	5% [36, 37]	HKI-272
HER2 overexpression	5–9% [38]	—	3–5% [38]	Afatinib, Neratinib, Trastuzumab
HER2 mutation	2% [38]	—	1% [38]
HER2 amplification	0,9% [38]	—	—
FGFR1 amplification	1–3% [39]	4–6% [34]	20% [40, 41]	BGJ398, AZD4547, JNJ-42756493
FGFR rearrangement	Very rare [42]	—	1% [42]
MET amplification	3–21% [43–45]	2% [43–45]	3–21% [43–45]	Crizotinib, Tivantinib
MET mutation	2% [38]	—	1% [38]
DDR2 mutation	1% [46–48]	—	4% [46–48]	Dasatinib
ALK rearrangement	2–7% [33]	—	1% [49]	Crizotinib, alectinib, Ceritinib
ROS1 rearrangement	1,7% [50]	—	—	TAE684
RET rearrangement	0,9% [7, 51]	—	—	Vandetanib, ASP3026, Cabozantinib, Foretinib
KIT mutation	—	6% [34]	—	Axitinib, Imatinib
PDGFRA amplification	3.8% [52]	2% [34]	8.7% [32]	Crenolanib

NSCLC: non-small-cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; SCLC: small-cell lung cancer.